Depomed, Inc. (DEPO)

Check out top investors' recommendation for DEPO
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Depomed, Inc., a specialty pharmaceutical company, focuses on developing products for pain and other conditions, and diseases of the central nervous system in the United States. The company primarily offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Glumetza, a metformin hydrochloride extended release tablets for use in adults with type 2 diabetes. It is also involved in the clinical development of two product candidates, comprising Serada, which completed Phase III clinical trials for the treatment of menopausal hot flashes; and DM-1992 that completed a Phase II trial for Parkinson's disease. The company sells its Gralise products to wholesalers and retail pharmacies. Depomed, Inc. has license and collaboration agreements with Santarus, Inc.; Covidien, Ltd.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Merck & Co., Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Abbott Products Inc.; Patheon Puerto Rico, Inc.; Valeant Pharmaceuticals International, Inc.; and PharmaNova, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Scott Henry Roth Capital Partners LLC Buy   Mar 02, '18     10.00  Mar 02, '19  N/A 
Scott Henry Roth Capital Partners LLC Buy   Aug 08, '17     12.00  Aug 08, '18  N/A 
Jason Butler JMP Securities Buy   Mar 30, '17     16.00  Mar 30, '18  N/A 
Scott Henry Roth Capital Partners LLC Buy   Oct 21, '16     28.00  Oct 21, '17  N/A 
Jason Butler JMP Securities Buy   Aug 04, '16     22.00  Aug 04, '17  N/A 
Jason Gerberry Leerink Swann Llc Buy   Mar 10, '16   15.19    Mar 10, '17  N/A 
Ami Fadia UBS Buy   Feb 09, '16   15.81  22.00  Feb 09, '17  39.15% 
David Amsellem Piper Jaffray Buy   Feb 08, '16   15.22  23.00  Feb 08, '17  51.12% 
Scott Henry Roth Capital Partners LLC Buy   Nov 11, '15   19.90  24.00  Nov 11, '16  20.60% 
Ken Trbovich C.K. Cooper & Company Buy   Oct 20, '15   17.07  35.00  Oct 20, '16  37.96% 
Scott Henry Roth Capital Partners LLC Buy   Sep 30, '15   18.85  21.00  Sep 30, '16  26.74% 
Scott Henry Roth Capital Partners LLC Buy   Jul 14, '15   30.81  33.00  Jul 14, '16  7.11% 
Scott Henry Roth Capital Partners LLC Buy   May 12, '15   20.43    May 12, '16  -13.22% 
Scott Henry Roth Capital Partners LLC Buy   Apr 06, '15   22.80  30.00  Apr 06, '16  31.58% 
Scott Henry Roth Capital Partners LLC Buy   Feb 24, '15   22.71    Feb 24, '16  -26.24% 
Scott Henry Roth Capital Partners LLC Buy   Jan 16, '15   20.20  25.00  Jan 16, '16  23.76% 
Jason Butler JMP Securities Buy   Dec 18, '13   9.82  11.00  Dec 18, '14  55.40% 
Jason Butler JMP Securities Buy   Oct 22, '13   7.67  10.00  Oct 22, '14  93.74% 
Scott Henry Roth Capital Partners LLC Buy   Jul 30, '13   6.38  9.00  Jul 30, '14  67.55% 
Jason Butler JMP Securities Buy   Apr 07, '13   5.43  9.00  Apr 07, '14  143.28% 
< previous12